Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2022.1124912 Oncology Correction Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma Prasopporn Sunisa 1 2 Suppramote Orawan 2 3 Ponvilawan Ben 2 Jamyuang Chanette 2 Chanthercrob Jantappapa 1 Chaiboonchoe Amphun 1 More-Krong Pimkanya 1 Kongsri Kamonchanok 1 Suntiparpluacha Monthira 1 Chanwat Rawisak 4 Korphaisarn Krittiya 5 Okada Seiji 6 Sampattavanich Somponnat 1 2 Jirawatnotai Siwanon 1 2 * 1 Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 2 Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 3 Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand 4 HepatoPancreato-Biliary Surgery Unit, Department of Surgical Oncology, National Cancer Institute, Bangkok, Thailand 5 Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 6 Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Siwanon Jirawatnotai, Siwanon.jirwatnotai@mahidol.ac.th

This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology

 06 01 2023 2022 12 1124912 15 12 2022 19 12 2022 Copyright © 2023 Prasopporn, Suppramote, Ponvilawan, Jamyuang, Chanthercrob, Chaiboonchoe, More-Krong, Kongsri, Suntiparpluacha, Chanwat, Korphaisarn, Okada, Sampattavanich and Jirawatnotai 2023 Prasopporn, Suppramote, Ponvilawan, Jamyuang, Chanthercrob, Chaiboonchoe, More-Krong, Kongsri, Suntiparpluacha, Chanwat, Korphaisarn, Okada, Sampattavanich and Jirawatnotai

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma by Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S and Jirawatnotai S (2022) Front. Oncol. 12:1021632. doi: 10.3389/fonc.2022.1021632 SMAC mimetics LCL161 Gemcitabine plus Cisplatin therapy multidrug resistance cholangiocarcinoma acquired vulnerability

In the published article, there was an error in the Funding statement. There was one missing funding agency from our manuscript. The correct Funding statement appears below.

Funding

This study was funded by grants from the National Science and Technology Development Agency (NSTDA) of Thailand, the Japan Science and Technology Agency, and the National Institute of Allergy and Infectious Diseases of the United States as part of the e-ASIA Joint Research Program (e-ASIA JRP); the NSTDA (P-15-50208), the National Research Council of Thailand (NRCT) R016441034, the Advanced Research in Pharmacology Fund, Siriraj Foundation (D003421), and by Mahidol University (Basic Research Fund, and the grant of fiscal year 2022).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.